MX2016006336A - Compuestos pirazolopirimidina. - Google Patents

Compuestos pirazolopirimidina.

Info

Publication number
MX2016006336A
MX2016006336A MX2016006336A MX2016006336A MX2016006336A MX 2016006336 A MX2016006336 A MX 2016006336A MX 2016006336 A MX2016006336 A MX 2016006336A MX 2016006336 A MX2016006336 A MX 2016006336A MX 2016006336 A MX2016006336 A MX 2016006336A
Authority
MX
Mexico
Prior art keywords
pyrazolopyrimidine compounds
formula
pyrazolopyrimidine
compounds
pharmaceutically acceptable
Prior art date
Application number
MX2016006336A
Other languages
English (en)
Inventor
Radoslaw Laufer
Yong Liu
Sze-Wan Li
Heinz W Pauls
Ng Grace
Kumar B Patel Narendra
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of MX2016006336A publication Critical patent/MX2016006336A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Las presentes enseñanzas proveen un compuesto representado por la siguiente fórmula estructural: (ver Fórmula) o una sal farmacéuticamente aceptable del mismo; también se describen composiciones farmacéuticas y métodos de uso de las mismas.
MX2016006336A 2012-11-16 2014-11-14 Compuestos pirazolopirimidina. MX2016006336A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261727581P 2012-11-16 2012-11-16
US201361808152P 2013-04-03 2013-04-03
PCT/CA2013/000957 WO2014075168A1 (en) 2012-11-16 2013-11-15 Pyrazolopyrimidine compounds
PCT/CA2014/051091 WO2015070349A1 (en) 2012-11-16 2014-11-14 Pyrazolopyrimidine compounds

Publications (1)

Publication Number Publication Date
MX2016006336A true MX2016006336A (es) 2016-09-06

Family

ID=50730425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006336A MX2016006336A (es) 2012-11-16 2014-11-14 Compuestos pirazolopirimidina.

Country Status (24)

Country Link
US (8) US9573954B2 (es)
EP (2) EP2920181B1 (es)
JP (1) JP6377068B2 (es)
CN (1) CN105793261B (es)
AU (1) AU2013344716B2 (es)
BR (1) BR112016010080B1 (es)
CA (1) CA2889919C (es)
CY (1) CY1120480T1 (es)
DK (1) DK3068786T3 (es)
ES (1) ES2686097T3 (es)
HR (1) HRP20181041T1 (es)
HU (1) HUE039351T2 (es)
IL (1) IL245187B (es)
LT (1) LT3068786T (es)
ME (1) ME03093B (es)
MX (1) MX2016006336A (es)
NZ (1) NZ707432A (es)
PL (1) PL3068786T3 (es)
PT (1) PT3068786T (es)
RS (1) RS57481B1 (es)
SG (1) SG11201603102TA (es)
SI (1) SI3068786T1 (es)
TW (1) TWI679201B (es)
WO (2) WO2014075168A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075168A1 (en) 2012-11-16 2014-05-22 University Health Network Pyrazolopyrimidine compounds
EA029372B1 (ru) * 2013-11-15 2018-03-30 Юниверсити Хелс Нетуорк Пиразолопиримидиновые соединения
JP2017526702A (ja) * 2014-09-08 2017-09-14 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ＰＰＡＲ−γアゴニストを投与する段階を含む、癌を治療する方法
KR20170082577A (ko) 2014-11-06 2017-07-14 리소소말 테라퓨틱스 인크. 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
EP3215509B1 (en) 2014-11-06 2020-02-26 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
AU2016284638B2 (en) * 2015-06-24 2020-01-23 Curovir Ab Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
JP7046827B2 (ja) 2016-04-06 2022-04-04 リソソーマル・セラピューティクス・インコーポレイテッド イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
MX2018012211A (es) 2016-04-06 2019-03-28 Lysosomal Therapeutics Inc Compuestos de pirazol[1,5-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
CA3020310A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
SG11201809693SA (en) 2016-05-05 2018-11-29 Lysosomal Therapeutics Inc SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
FI3484888T5 (fi) 2016-07-18 2024-02-26 Univ Health Network Ttk:n estäjän kiinteitä muotoja
CN111194317A (zh) 2017-07-28 2020-05-22 林伯士拉克许米公司 Tyk2抑制剂与其用途
WO2019023786A1 (en) * 2017-08-01 2019-02-07 University Health Network COMBINED THERAPIES FOR THE INHIBITION OF TTK PROTEIN KINASE
AU2019273871A1 (en) * 2018-05-23 2020-12-10 University Health Network Methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (SKA3) gene
MX2021004769A (es) 2018-10-30 2021-08-24 Kronos Bio Inc Compuestos, composiciones, y metodos para modular la actividad cdk9.
CN111377925B (zh) * 2018-12-28 2024-03-12 四川科伦博泰生物医药股份有限公司 嘌呤类衍生物、其制备方法及其在医药上的应用
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
CN113773324B (zh) * 2021-09-07 2022-07-26 武汉九州钰民医药科技有限公司 抗肿瘤药cfi-402257的合成制备工艺
CN116396298A (zh) * 2023-06-06 2023-07-07 四川维亚本苑生物科技有限公司 CDK Ligand-1的中间体XII及CDK Ligand-1的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021556A (en) * 1972-06-08 1977-05-03 Icn Pharmaceuticals, Inc. Xanthine oxidase inhibitors
JPH04156452A (ja) 1990-10-19 1992-05-28 Konica Corp 新規な写真用カプラー
JPH04156453A (ja) 1990-10-19 1992-05-28 Konica Corp 新規な写真用カプラー
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6124289A (en) 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
WO2000059907A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
AU7737900A (en) 1999-09-30 2001-04-30 Neurogen Corporation Amino substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines
US6372743B1 (en) * 1999-09-30 2002-04-16 Neurogen Corporation Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
ATE302203T1 (de) 2002-03-07 2005-09-15 Smithkline Beecham Corp Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
AU2003227437A1 (en) 2002-04-23 2003-11-10 Shionogi And Co., Ltd. PYRAZOLO(1,5-a)PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
FR2842809A1 (fr) 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
CA2494700C (en) 2002-08-26 2011-06-28 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
JP2006501260A (ja) 2002-09-04 2006-01-12 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
EP1537116B1 (en) 2002-09-04 2010-06-02 Schering Corporation Pyrazolopyrimidines suitable for the treatment of cancer diseases
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004052315A2 (en) 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
EP1608652A1 (en) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
US7834014B2 (en) 2003-04-09 2010-11-16 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
WO2004092170A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
EP1699800B1 (en) 2003-12-23 2010-02-10 Novartis AG Bicyclic heterocyclic p-38 kinase inhibitors
AR047969A1 (es) 2004-02-25 2006-03-15 Schering Corp Pirazolotriazinas como inhibidores de quinasa
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CA2627623C (en) 2005-10-06 2014-04-22 Schering Corporation Methods for inhibiting protein kinases
EP1873157A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
MY146474A (en) 2006-11-06 2012-08-15 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
EP2178375B1 (en) * 2007-07-20 2014-09-24 Merck Sharp & Dohme Corp. Pyrazoloý1,5-a¨pyrimidine derivatives
US20100029657A1 (en) 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
GB0908957D0 (en) 2009-05-22 2009-07-01 Ucb Pharma Sa Therapeutic agents
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2525659B1 (en) 2010-01-19 2019-02-27 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
CN103038235B (zh) 2010-06-01 2015-07-29 拜耳知识产权有限责任公司 取代的咪唑并吡嗪
US20120083498A1 (en) 2010-06-17 2012-04-05 Fatah Kashanchi Modulators of Viral Transcription, and Methods and Compositions Therewith
US20120149708A1 (en) 2010-06-17 2012-06-14 George Mason University Modulators of viral transcription, and methods and compositions therewith
BR112012033117A2 (pt) 2010-06-24 2016-11-22 Gilead Sciences Inc pirazolo[1,5-a]pirimidinas como agentes antivirais
EP2402337A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US20140135319A1 (en) 2010-12-17 2014-05-15 Bayer Intellectual Property Gmbh 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103415518A (zh) 2010-12-17 2013-11-27 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪
WO2012080230A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20140038953A1 (en) 2011-01-21 2014-02-06 The General Hospital Corporation Compositions and methods for cardiovascular disease
WO2012136531A1 (en) 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Substituted imidazopyridines and intermediates thereof
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
RU2014120168A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические азагетероциклы и аналоги в качестве модуляторов сиртуина
WO2014075168A1 (en) * 2012-11-16 2014-05-22 University Health Network Pyrazolopyrimidine compounds

Also Published As

Publication number Publication date
IL245187A0 (en) 2016-06-30
EP3068786A1 (en) 2016-09-21
EP2920181B1 (en) 2019-01-09
HRP20181041T1 (hr) 2018-09-21
LT3068786T (lt) 2018-08-27
US20170320881A1 (en) 2017-11-09
AU2013344716B2 (en) 2018-03-01
BR112016010080B1 (pt) 2020-12-29
US10570143B2 (en) 2020-02-25
CY1120480T1 (el) 2019-07-10
PT3068786T (pt) 2018-07-26
SI3068786T1 (sl) 2018-09-28
CA2889919A1 (en) 2014-05-22
AU2013344716A1 (en) 2015-05-14
DK3068786T3 (en) 2018-07-16
PL3068786T3 (pl) 2018-10-31
US9573954B2 (en) 2017-02-21
BR112016010080A8 (pt) 2020-04-14
WO2015070349A1 (en) 2015-05-21
JP2015537008A (ja) 2015-12-24
EP2920181A1 (en) 2015-09-23
US20190040074A1 (en) 2019-02-07
US20220204511A1 (en) 2022-06-30
US9657025B2 (en) 2017-05-23
EP3068786B1 (en) 2018-06-06
SG11201603102TA (en) 2016-05-30
US20170217966A1 (en) 2017-08-03
CN105793261B (zh) 2018-11-30
US20160137651A1 (en) 2016-05-19
US20210009595A1 (en) 2021-01-14
NZ707432A (en) 2020-01-31
US10106545B2 (en) 2018-10-23
CN105793261A (zh) 2016-07-20
TW201605860A (zh) 2016-02-16
TWI679201B (zh) 2019-12-11
US20150299203A1 (en) 2015-10-22
US20190322669A1 (en) 2019-10-24
EP3068786A4 (en) 2017-04-12
US10167289B2 (en) 2019-01-01
ME03093B (me) 2019-01-20
RS57481B1 (sr) 2018-10-31
EP2920181A4 (en) 2016-07-27
JP6377068B2 (ja) 2018-08-22
HUE039351T2 (hu) 2018-12-28
WO2014075168A1 (en) 2014-05-22
IL245187B (en) 2019-12-31
CA2889919C (en) 2021-08-17
ES2686097T3 (es) 2018-10-16

Similar Documents

Publication Publication Date Title
MX2016006336A (es) Compuestos pirazolopirimidina.
PH12020550552A1 (en) Inhibitors of hepatitis c virus
CA2875877C (en) Syk inhibitors
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
AU2012214029A8 (en) Rorgammat inhibitors
PH12014502605A1 (en) Uracyl spirooxetane nucleosides
UA110354C2 (uk) Противірусні сполуки
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
IN2014MN02106A (es)
IN2014MN02652A (es)
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
IN2015DN01119A (es)
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
MX353762B (es) Inhibicion de il17 e ifn-gamma para el tratamiento de inflamacion autoinmune.
MX348726B (es) Inhibición del il17 e ifn-gamma para el tratamiento de inflamación autoinmune.
MX364400B (es) Compuestos de tetraciclina.
IN2014CN04449A (es)
IN2014DN07996A (es)
MX2013000009A (es) Procedimiento de preparacion de la sal de l-arginina de perindoprilo.
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
PH12015501056A1 (en) 2-pyridone compound
MX362994B (es) Preparacion farmaceutica que comprende un derivado de aminopirazol.

Legal Events

Date Code Title Description
FG Grant or registration